Agios Pharmaceuticals (NASDAQ:AGIO) CEO Brian Goff Sells 18,703 Shares

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) CEO Brian Goff sold 18,703 shares of the company’s stock in a transaction that occurred on Tuesday, December 30th. The shares were sold at an average price of $27.09, for a total transaction of $506,664.27. Following the completion of the transaction, the chief executive officer owned 136,583 shares of the company’s stock, valued at $3,700,033.47. This trade represents a 12.04% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Agios Pharmaceuticals Stock Down 0.1%

Shares of AGIO stock opened at $27.18 on Friday. Agios Pharmaceuticals, Inc. has a 12-month low of $22.24 and a 12-month high of $46.00. The firm has a fifty day moving average of $32.20 and a 200-day moving average of $35.96. The company has a market capitalization of $1.58 billion, a price-to-earnings ratio of -3.88 and a beta of 0.89.

Agios Pharmaceuticals (NASDAQ:AGIO) last announced its earnings results on Thursday, October 30th. The biopharmaceutical company reported ($1.78) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.93) by $0.15. The firm had revenue of $12.88 million during the quarter, compared to analyst estimates of $10.49 million. Agios Pharmaceuticals had a negative net margin of 895.86% and a negative return on equity of 28.35%. The company’s revenue for the quarter was up 43.3% compared to the same quarter last year. During the same period in the prior year, the business earned $16.22 EPS. On average, equities analysts expect that Agios Pharmaceuticals, Inc. will post -6.85 EPS for the current year.

Analyst Upgrades and Downgrades

A number of equities research analysts recently issued reports on AGIO shares. Royal Bank Of Canada lowered Agios Pharmaceuticals from an “outperform” rating to a “sector perform” rating and dropped their target price for the company from $57.00 to $28.00 in a research report on Wednesday, November 19th. Leerink Partners raised their price target on shares of Agios Pharmaceuticals from $34.00 to $40.00 and gave the stock an “outperform” rating in a research note on Friday, December 26th. HC Wainwright increased their price objective on shares of Agios Pharmaceuticals from $48.00 to $62.00 and gave the stock a “buy” rating in a research note on Wednesday, December 24th. Weiss Ratings restated a “sell (d)” rating on shares of Agios Pharmaceuticals in a report on Monday. Finally, Wall Street Zen lowered shares of Agios Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Saturday, November 22nd. One investment analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, Agios Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus target price of $38.89.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. First Horizon Corp acquired a new position in shares of Agios Pharmaceuticals during the third quarter valued at about $45,000. NewEdge Advisors LLC bought a new position in Agios Pharmaceuticals in the 1st quarter valued at about $40,000. Quantbot Technologies LP acquired a new position in Agios Pharmaceuticals during the 3rd quarter valued at about $79,000. Mirae Asset Global Investments Co. Ltd. increased its holdings in Agios Pharmaceuticals by 16.7% during the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,237 shares of the biopharmaceutical company’s stock worth $74,000 after purchasing an additional 320 shares in the last quarter. Finally, PNC Financial Services Group Inc. increased its holdings in Agios Pharmaceuticals by 23.4% during the 2nd quarter. PNC Financial Services Group Inc. now owns 4,419 shares of the biopharmaceutical company’s stock worth $147,000 after purchasing an additional 837 shares in the last quarter.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc is a biopharmaceutical company founded in 2008 as a spin-out from research at Dana-Farber Cancer Institute and the Broad Institute. Headquartered in Cambridge, Massachusetts, Agios focuses on understanding and targeting cellular metabolism to develop novel therapies for cancer and rare genetic diseases. The company’s scientific platform integrates genomic discovery, metabolic profiling and precision medicine approaches to identify and advance small-molecule candidates that correct or exploit metabolic dysfunction.

Agios’s lead products are IDH (isocitrate dehydrogenase) inhibitors that target specific cancer mutations.